CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sigilon Therapeutics, a biopharmaceutical company creating functional cures for chronic diseases using its Shielded Living Therapeutics™ platform, today announced the addition to its patent portfolio of U.S. Patent Nos. 10,285,949 and 10,292,936, which are entitled “Modified alginates for cell encapsulation and cell therapy.”
The patents are exclusively licensed to Sigilon and were granted to the Massachusetts Institute of Technology and The Children’s Medical Center Corporation. These patents are based on foundational research by Sigilon Co-Founders Daniel G. Anderson, Ph.D., and Robert Langer, Sc.D. This research resulted in the invention of various chemically modified alginates that can protect implanted cells, biomaterials and medical devices from fibrosis and other immune responses to foreign bodies.
“When we developed the core technology, we recognized the potential for this platform to be used to provide novel therapeutic options for patients,” Dr. Langer said. “We are proud of the efforts at Sigilon to bring this important technology to a broad range of serious chronic diseases.”
Sigilon’s broad and deep patent portfolio covers all elements of Sigilon’s product platform — from underlying chemistry and cells to encapsulation — as well as therapeutic uses in core diseases. The portfolio consists of 18 patent families (exclusively licensed and Sigilon-owned), including seven U.S. patents, five ex-U.S. patents and more than 70 pending patent applications in all major markets.
“The ongoing enrichment of Sigilon’s intellectual property portfolio places us in a position of strength as we continue to expand the therapeutic opportunities for Shielded Living Therapeutics™ products,” said Rogerio Vivaldi, M.D., MBA, President and Chief Executive Officer of Sigilon. “Our mission is to provide pioneering therapies for patients with serious chronic diseases, liberating them from the burdens of present-day therapies.”
About Sigilon Therapeutics
Sigilon Therapeutics is a biopharmaceutical company creating functional cures for chronic diseases using its Shielded Living Therapeutics™ platform. To create a Shielded Living Therapeutics™ product, we engineer novel human cells that we encase in a proprietary immune-shielding matrix and place in the body. These Shielded Living Therapeutics™ products then produce therapeutic proteins in a programmable and durable fashion, without generating fibrosis or immune rejection. Sigilon was founded and created by Flagship Pioneering in conjunction with Daniel G. Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.